IND For TIL Therapy With Obsidian Therapeutics' Paul Wotton, Ph.D.
Business Of Biotech · 47 minutes ·

IND For TIL Therapy With Obsidian Therapeutics' Paul Wotton, Ph.D.

On this episode of The Business of Biotech, Obsidian Therapeutics CEO Paul Wotton, Ph.D. takes us behind the scenes to reveal what precipitated the FDA's clearance of its IND application for a novel, engineered tumor-infiltrating lymphocyte therapy called OBX-115.  Learn how the company navigated the regulatory path for a first-of-its-kind biologic therapy developed in partnership with the University of Texas MD Anderson Cancer Center that Dr. Wotton says, should it succeed, will eliminate the patient risk associated with concomitant IL2 therapy and improve clinical outcomes for certain patients with metastatic melanoma. We also get an update on outcomes from Obsidian's unique approach to solving COVID-19 challenges covered on episode 9 of the Business of Biotech.

Comments (0)

You Must Be Logged In To Comment

Similar podcasts

Mind Tap with Alternative Therapeutics

Foodist with Darya Rose, Ph.D

Bone, Stone, and Obsidian

Better With Paul

Obsidian Blade • The Frequency

Therapy For The Heart

Therapy for Black Girls

Too Cheap For Therapy